1. Home
  2. MBIO vs RENX Comparison

MBIO vs RENX Comparison

Compare MBIO & RENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MBIO

Mustang Bio Inc.

N/A

Current Price

$0.42

Market Cap

4.1M

Sector

Health Care

ML Signal

N/A

Logo RenX Enterprises Corp. Common Stock

RENX

RenX Enterprises Corp. Common Stock

N/A

Current Price

$1.28

Market Cap

3.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
MBIO
RENX
Founded
2015
2021
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1M
3.9M
IPO Year
2023
2023

Fundamental Metrics

Financial Performance
Metric
MBIO
RENX
Price
$0.42
$1.28
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
32.2K
★ 82.3K
Earning Date
11-24-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 98.99
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $8,220,449.00
Revenue This Year
N/A
$109.28
Revenue Next Year
$405.45
$53.56
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 3860.67
52 Week Low
$0.35
$0.84
52 Week High
$1.44
$203.14

Technical Indicators

Market Signals
Indicator
MBIO
RENX
Relative Strength Index (RSI) 49.70 49.38
Support Level $0.35 $0.89
Resistance Level $0.43 $2.16
Average True Range (ATR) 0.04 0.12
MACD 0.01 0.04
Stochastic Oscillator 47.80 81.75

Price Performance

Historical Comparison
MBIO
RENX

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

About RENX RenX Enterprises Corp. Common Stock

RenX Enterprises Corp is engaged in real property development using purpose-built, prefabricated modules constructed from both wood and steel. The Company's operations mainly focused on the acquisition, entitlement, and development of residential properties in high-growth markets across the United States. These efforts included the direct acquisition of land, strategic investments in real estate entities, and joint venture partnerships targeting green, single-family, and multifamily housing projects. The company operates in four segments: real estate development, technology, compost sales, and logistics. The company generates from the compost sales.

Share on Social Networks: